- Home
- ZENV vs NVCT Comparison
ZENV vs NVCT Comparison
Compare ZENV & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- NVCT
- Stock Information
- Founded
- ZENV 2005
- NVCT 2020
- Country
- ZENV Brazil
- NVCT United States
- Employees
- ZENV N/A
- NVCT N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- ZENV Technology
- NVCT Health Care
- Exchange
- ZENV Nasdaq
- NVCT Nasdaq
- Market Cap
- ZENV 63.3M
- NVCT 119.4M
- IPO Year
- ZENV 2021
- NVCT 2022
- Fundamental
- Price
- ZENV $1.62
- NVCT $4.52
- Analyst Decision
- ZENV
- NVCT Strong Buy
- Analyst Count
- ZENV 0
- NVCT 1
- Target Price
- ZENV N/A
- NVCT $21.00
- AVG Volume (30 Days)
- ZENV 72.4K
- NVCT 91.0K
- Earning Date
- ZENV 11-18-2024
- NVCT 11-05-2024
- Dividend Yield
- ZENV N/A
- NVCT N/A
- EPS Growth
- ZENV N/A
- NVCT N/A
- EPS
- ZENV N/A
- NVCT N/A
- Revenue
- ZENV $173,594,726.00
- NVCT N/A
- Revenue This Year
- ZENV $25.56
- NVCT N/A
- Revenue Next Year
- ZENV $6.02
- NVCT N/A
- P/E Ratio
- ZENV N/A
- NVCT N/A
- Revenue Growth
- ZENV 23.49
- NVCT N/A
- 52 Week Low
- ZENV $1.00
- NVCT $4.44
- 52 Week High
- ZENV $3.88
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- ZENV 54.93
- NVCT 37.50
- Support Level
- ZENV $1.61
- NVCT $4.48
- Resistance Level
- ZENV $1.78
- NVCT $5.34
- Average True Range (ATR)
- ZENV 0.12
- NVCT 0.37
- MACD
- ZENV -0.00
- NVCT 0.07
- Stochastic Oscillator
- ZENV 48.48
- NVCT 8.89
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.